Drug Prices
The Centers for Medicare & Medicaid Aug. 15 announced it negotiated lower prices with drug makers for 10 high-cost, sole-source drugs, with the new prices becoming effective in 2026 for individuals with Medicare Part D coverage.
Our shared focus with Congress and Administration is on providing relief from the pandemic, ensuring a smooth recovery, and rebuilding a better health care system for the future. The American Hospital Association continues to incorporate principles that promote improved affordability, value, and…
The Centers for Medicare & Medicaid Services July 16 released its final guidance on the Medicare Prescription Payment Plan which will begin next year.
The Department of Health and Human Services June 26 announced beneficiary coinsurance reductions for 64 prescription drugs available through Medicare Part B.
Blog, infographic highlight how increasing drug prices and shortages are jeopardizing access to care
The AHA May 22 released a new infographic and blog highlighting how increasing drug prices and shortages are jeopardizing patient access to hospital care and exacerbating challenges hospitals are experiencing.
The inability of many patients to obtain needed drug therapies due to either high prices or shortages has negatively affected patient outcomes.1 Nearly 30% of Americans say they haven’t taken their medication as prescribed due to high drug prices, and it is estimated that more than 1.1 million…
Drug companies continue to introduce new drugs at record prices. The median annual list price for new drugs in 2023 was $300,000, an increase of 35% over the previous year.
Glucagon-like peptide-1 agonist drugs have been surging in popularity, and manufacturers are scurrying to keep up with demand. Overall, the GLP-1 market is expected to experience annual growth exceeding 20% and will hit $133 billion worldwide by 2030, according to a MarketWatch report from February…
The Centers for Medicare & Medicaid Services May 3 announced the opening of the comment period for the Inflation Reduction Act’s Medicare Drug Price Negotiation Program, which will negotiate prices with drug makers for certain high-cost, sole-source drugs and apply them beginning in 2026.…
While recent data suggest that some hospital and health system finances have experienced modest stabilization from historic lows in 2022, the hospital field is still far from where it needs to be to meet the demand for care, invest in new and promising technologies and interventions, and stand…